Shionogi
Shionogi and Maze Therapeutics announce worldwide exclusive licensing agreement for novel Pompe disease candidate
May 10, 2024Sales and Marketing Pompe disease, Rare Diseases, Shionogi, licensing agreement, maze therapeutics
Japanese pharmaceutical company Shionogi and US-based Maze Therapeutics have finalised an exclusive worldwide license agreement for MZE001, a novel therapeutic …
Shionogi’s novel antibiotic selected for UK pilot subscription reimbursement model
December 21, 2020Sales and Marketing NICE, Shionogi, antibiotic
Japanese pharmaceutical company Shionogi today announced that NICE and NHS England and Improvement (NHSE&I) have selected its novel antibiotic Fetcroja …
Shionogi’s Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease
December 12, 2019Sales and Marketing England, Mulpleo, NICE, Scotland, Scottish Medicines Consortium, Shionogi, Wales
Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and …
First novel, single-dose flu drug approved in US in almost 20 years
October 25, 2018Sales and Marketing FDA, Shionogi, Xofluza, flu, influenza, pharma
The FDA has announced that it has approved the first single-dose flu drug with a novel mechanism of action in …
FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit
February 8, 2018Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma
Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.
ViiV completes BMS HIV pipeline purchase
February 23, 2016Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV
ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …
GSK mulls $27 billion ViiV sell-off
October 23, 2014Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV
After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …
Shionogi and ViiV strike new HIV deal
October 30, 2012Research and Development, Sales and Marketing Atripla, Dolutegravir, HIV, Shionogi, ViiV
HIV specialist firm ViiV Healthcare has announced a new deal with Japan’s Shionogi on a promising new treatment. ViiV Healthcare …
Shionogi opens UK office
July 9, 2012Research and Development, Sales and Marketing Crestor, Japan, Osaka, Shionogi, cholesterol
Japanese pharma firm Shionogi & Co has opened a new office in London and pledged to expand into Europe. Osaka-based …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
